How should I evaluate and initially manage a patient with unexplained anemia, jaundice, dark urine, or elevated lactate dehydrogenase suggestive of hemolysis?

Hemolysis Work-Up

Begin by confirming hemolysis with the core laboratory triad: markedly low or undetectable haptoglobin (<0.2 g/L), elevated lactate dehydrogenase (LDH >500 U/L, often >1200 U/L in active hemolysis), and elevated unconjugated (indirect) bilirubin. 1, 2, 3, 4

Initial Laboratory Confirmation

Core hemolysis markers:

• Haptoglobin – the most sensitive marker; becomes depleted as it binds free hemoglobin from lysed red cells 4, 5
• Lactate dehydrogenase (LDH) – released from lysed red cells; values >500 U/L strongly suggest hemolysis 1, 2, 4
• Unconjugated (indirect) bilirubin – elevated due to breakdown of hemoglobin 1, 3, 6
• Reticulocyte count – typically elevated (>120×10⁹/L or reticulocyte index >2-3), indicating marrow compensation; however, may be inappropriately low in early acute hemolysis, vitamin deficiency, or bone marrow involvement 1, 3, 5, 7

Essential baseline tests:

• Complete blood count with red cell indices to assess severity and type of anemia (normocytic, microcytic, macrocytic) 1, 3
• Peripheral blood smear – critical for identifying red cell morphology 1, 3, 5

Categorize by Direct Antiglobulin Test (DAT/Coombs)

The DAT is the cornerstone test that divides hemolytic anemia into immune versus non-immune causes. 1, 3, 8

DAT-Positive (Immune-Mediated Hemolysis)

If DAT is positive, pursue autoimmune hemolytic anemia workup: 1, 3

• Autoimmune serology to identify underlying autoimmune disorders 1
• Drug history – specifically ask about ribavirin, rifampin, dapsone, interferon, cephalosporins, penicillins, NSAIDs, quinine/quinidine, fludarabine, ciprofloxacin, lorazepam, diclofenac 1
• Protein electrophoresis and cryoglobulin analysis to exclude lymphoproliferative disorders 1
• Infectious workup – viral/bacterial causes including mycoplasma 1

DAT-Negative (Non-Immune Hemolysis)

If DAT is negative, systematically evaluate for non-immune causes based on peripheral smear findings and clinical context: 3, 5, 8

Examine peripheral blood smear for specific morphology:

• Schistocytes (>1%) – indicates thrombotic microangiopathy (TMA); requires urgent ADAMTS13 activity level and inhibitor titer 2, 5
• Spherocytes – suggests hereditary spherocytosis; confirm with eosin-5'-maleimide (EMA) binding test and family history 3, 6
• Sickle cells – indicates sickle cell disease; confirm with hemoglobin electrophoresis 3, 5
• Bite cells or blister cells – suggests G6PD deficiency, especially with oxidative stress history 1, 3
• Echinocytes – may indicate pyruvate kinase deficiency, particularly post-splenectomy 3
• Parasites – malaria or babesiosis; requires immediate treatment 6, 5

Second-Line Testing Based on Clinical Context

For suspected thrombotic microangiopathy (TMA):

• ADAMTS13 activity level and inhibitor titer – order urgently; <10% indicates TTP 2
• Platelet count – thrombocytopenia is part of the TMA triad 2
• Creatinine and urinalysis – assess for renal involvement (hematuria/proteinuria) 2
• Prothrombin time, activated PTT, fibrinogen – exclude DIC 2
• Complement testing (C3, C4, CH50) – for suspected complement-mediated atypical HUS 2

For suspected hereditary hemolytic anemia (DAT-negative with family history):

• Hemoglobin phenotyping – identifies hemoglobinopathies (sickle cell, thalassemia, hemoglobin C, unstable hemoglobins) 3, 5
• Eosin-5'-maleimide (EMA) binding test – screens for hereditary spherocytosis and other membranopathies 3, 5
• G6PD enzyme assay – especially in males with oxidative stress exposure 1, 3
• Pyruvate kinase and other red cell enzyme assays – for transfusion-dependent patients with undiagnosed anemia 3
• Paroxysmal nocturnal hemoglobinuria (PNH) screening by flow cytometry – particularly if intravascular hemolysis features present 1, 3

For intravascular hemolysis features (markedly elevated LDH, very low haptoglobin):

• Free hemoglobin in plasma 1
• Hemosiderinuria – pathognomonic for chronic intravascular hemolysis 7
• PNH flow cytometry 1, 3
• Evaluate for mechanical causes – prosthetic heart valves, ventricular assist devices, intravascular stents 1, 7

Additional Contextual Testing

Rule out other causes and assess complications:

• Vitamin B12 and folate levels – exclude megaloblastic anemia as alternative diagnosis 1, 3
• Iron studies (ferritin, transferrin saturation) – may be disproportionately elevated in chronic hemolysis even without transfusion; normal ferritin excludes iron deficiency 3, 4
• Copper level – if refractory or bone marrow failure suspected 1
• Ceruloplasmin and 24-hour urinary copper – if young patient with acute hemolysis and liver disease (Wilson's disease) 1
• DIC panel (PT/INR, fibrinogen) – if concern for consumptive coagulopathy 1
• Methemoglobin level – if cyanosis or drug exposure 1

If no diagnosis after above workup:

• Bone marrow examination with cytogenetic analysis – evaluate for myelodysplastic syndromes, infiltrative disease, or ineffective erythropoiesis 1, 3

Critical Pitfalls to Avoid

Do not dismiss hemolysis based on:

• Normal or only mildly elevated reticulocyte count – reticulocytopenia occurs in 20-40% of autoimmune hemolytic anemia cases and indicates poor prognosis; also seen in early acute hemolysis, vitamin deficiency, or marrow involvement 5, 7
• Absence of abundant schistocytes – low schistocyte counts can occur in early or evolving TMA; do not exclude TMA diagnosis 2
• Recent blood transfusion – can affect DAT and enzyme assay results; document timing 3

Do not delay plasma exchange while awaiting ADAMTS13 results if TTP is strongly suspected clinically – mortality increases with delayed treatment; initiate therapeutic plasma exchange and methylprednisolone 1g IV daily for 3 days immediately 2

Recognize specific high-risk presentations requiring urgent action:

• Acute liver failure with Coombs-negative hemolytic anemia – consider Wilson's disease; check ceruloplasmin, 24-hour urinary copper, slit-lamp exam for Kayser-Fleischer rings 1
• Hemolysis with thrombocytopenia and renal dysfunction – TMA triad; order ADAMTS13 urgently and prepare for plasma exchange 2
• New drugs or insect/spider/snake bites – obtain detailed exposure history 1